Episode 78: Covalently PD‐L1 Anchoring Drives Bispecific Nanostructure Assembly for Spatial Control of T Cell Recruitment and Activation
About this episode
This episode discusses a paper on a novel strategy for enhancing T cell recruitment and activation in cancer therapy through covalent PD-L1 anchoring.
**Monday Immune Engager** — our weekly pick from the latest immune-engager digest. **Paper:** [Covalently PD‐L1 Anchoring Drives Bispecific Nanostructure Assembly for Spatial Control of T Cell Recruitment and Activation](https://doi.org/10.1002/anie.5894316) **Authors:** Fengzhen Zhang, Yuhan Dong, Kailu Liu, Hui Hu, et al. **Journal:** Angewandte Chemie International Edition, 2025 **Why it matters:** Rather than passively blocking tumor immune checkpoints, this work shows it is possible to chemically hijack a tumor's own surface machinery to build synthetic nanostructures that simultaneously relieve immune suppression and actively recruit and activate T cells. **Summary** Current immune checkpoint therapies that block the PD-1/PD-L1 axis — the suppressive signaling pathway tumors use to exhaust T cells — benefit only around 20% of patients. Blocking the pathway removes an inhibitory signal but does not actively stimulate T cells to attack, a distinction the authors liken to releasing a parking brake without pressing the accelerator. This paper introduces a two-step "localized oxidation–covalent assembly" strategy designed to do both at once. The first component, the P1 probe, is…
People in this episode
Host: Raymond Ruff
Topics covered
- immune checkpoint therapy
- T cell activation
- nanostructures
- tumor immune response
- covalent assembly
Keywords
- PD-L1
- T cell recruitment
- immune suppression
- nanostructure assembly
- localized oxidation
Mentioned in this episode
Organizations: Angewandte Chemie International Edition
More episodes of Science TLDR
- Episode 79: Trending — Probability of a timely vocal response in mother-infant interaction and later psychiatric diagnosis: A case-control study
- Episode 77: Trending — People prefer to negotiate with women, even when outcomes are identical and gender is unknown
- Episode 76: Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors
Explore listener stats, chart rankings, contacts and more on the Science TLDR podcast page.